RESUMEN

The therapeutic efficiency of recombinant thymosin ß4 (rTß4) synthesized by us was studied in vivo on spontaneous CBRB mouse model that is adequate to human chronic dermatitis. Three applications of the drug during a week significantly alleviated symptoms of the disease in female mice, and in complex with subsequent antibacterial and antifungal therapy led to a pronounced and lasting (2 months) therapeutic effect. The results attest to a possibility of using rTß4 in combination with the known treatment protocols for chronic inflammatory diseases of the skin.

Asunto(s)

Dermatitis/tratamiento farmacológico , Proteínas Recombinantes/uso terapéutico , Timosina/uso terapéutico , Animales , Enfermedad Crónica/tratamiento farmacológico , Modelos Animales de Enfermedad , Femenino , Ratones